Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05014646 | Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients | active not recruiting | Phase 2 | 27 | City of Hope Medical CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05889221 | Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma | active not recruiting | N/A | 74 | Poitiers University HospitalOTHER | 1 | Apr 30, 2026 |
| clinicaltrials |
| NCT01500733 | PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | active not recruiting | Phase 2 | 86 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Apr 28, 2026 | clinicaltrials |
| NCT02732275 | DS-3201b in Participants With Lymphomas | active not recruiting | Phase 1 | 100 | Daiichi Sankyo Co., Ltd.INDUSTRY | 2 | Apr 28, 2026 | clinicaltrials |
| NCT02911571 | PRospective Multiple Myeloma Impact Study(PROMMIS) | active not recruiting | N/A | 250 | SkylineDxINDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT03863184 | Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL | active not recruiting | Phase 2 | 37 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT04384484 | Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma(LOTIS 5) | active not recruiting | Phase 3 | 440 | ADC Therapeutics S.A.INDUSTRY | 21 | Apr 28, 2026 | clinicaltrials |
| NCT05509751 | The SOAR Study: a Study of Geriatric Assessment and Exercise for Older Adults and Their Support Person(SOAR) | active not recruiting | N/A | 60 | Martine PutsOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT03178617 | High-Intensity Parent Intervention Program in Improving Learning and School Functioning in Latino Children With Acute Leukemia or Lymphoblastic Lymphoma | active not recruiting | N/A | 214 | City of Hope Medical CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT03479268 | Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT01382082 | Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy(CANTAB) | active not recruiting | — | 1,432 | University of Rochester NCORP Research BaseOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03141437 | Decision Aid Website in Helping to Make Decisions About Fertility in Participants With Cancer | active not recruiting | N/A | 130 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT04666038 | Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(BRUIN CLL-321) | active not recruiting | Phase 3 | 238 | Loxo Oncology, Inc.INDUSTRY | 24 | Apr 24, 2026 | clinicaltrials |
| NCT04960579 | P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma(MM) | active not recruiting | Phase 1 | 275 | Poseida Therapeutics, Inc.INDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05253118 | Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)(SPECTRUM) | active not recruiting | Phase 2 | 28 | Seoul National University HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT04246047 | Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma(DREAMM 7) | active not recruiting | Phase 3 | 494 | GlaxoSmithKlineINDUSTRY | 13 | Apr 23, 2026 | clinicaltrials |
| NCT05550948 | Use of Transcranial Photobiomodulation to Improve Cognition and Self-Reported Outcomes in Survivors of Childhood Cancer | active not recruiting | N/A | 44 | St. Jude Children's Research HospitalOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06205498 | Acalabrutinib Real World Italian obSErvational Study -ARISE(ARISE) | active not recruiting | — | 151 | AstraZenecaINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06868654 | China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma(DREAMM 7) | active not recruiting | Phase 3 | 72 | GlaxoSmithKlineINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06868667 | Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma(DREAMM 7) | active not recruiting | Phase 3 | 24 | GlaxoSmithKlineINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05507541 | TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | active not recruiting | Phase 2 | 10 | Mayo ClinicOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05757700 | Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma | active not recruiting | Phase 1 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT04544046 | Supportive Oncology Care At Home RCT | active not recruiting | N/A | 300 | Massachusetts General HospitalOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05392946 | Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study | active not recruiting | Phase 1 / Phase 2 | 49 | Mayo ClinicOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT07541755 | PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALL(PD1-VEN-CAG) | active not recruiting | Phase 3 | 40 | Fujian Medical University Union HospitalOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT04166565 | Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease(EMN19) | active not recruiting | Phase 2 | 41 | Stichting European Myeloma NetworkNETWORK | 3 | Apr 20, 2026 | clinicaltrials |
| NCT04561492 | Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma(PentiMyelo) | active not recruiting | Phase 2 | 45 | Nantes University HospitalOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT04939272 | Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | active not recruiting | Phase 1 / Phase 2 | 8 | City of Hope Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05020678 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers | active not recruiting | Phase 1 | 150 | Nkarta, Inc.INDUSTRY | 2 | Apr 20, 2026 | clinicaltrials |
| NCT04134325 | Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma | active not recruiting | Early Phase 1 | 10 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05888493 | A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma(LEDA) | active not recruiting | Phase 3 | 109 | Novartis PharmaceuticalsINDUSTRY | 11 | Apr 17, 2026 | clinicaltrials |
| NCT07162181 | Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers | active not recruiting | Phase 2 | 13 | Eli Lilly and CompanyINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04189757 | Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma | active not recruiting | Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT05317416 | Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant(MagnetisMM-7) | active not recruiting | Phase 3 | 854 | PfizerINDUSTRY | 27 | Apr 16, 2026 | clinicaltrials |
| NCT05456698 | Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy | active not recruiting | Phase 2 | 31 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT01424982 | Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia | active not recruiting | Phase 2 | 88 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02420860 | Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | active not recruiting | Phase 2 | 113 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02960555 | Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR) | active not recruiting | Phase 2 | 61 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03132454 | Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia | active not recruiting | Phase 1 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03680586 | Ultra Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma | active not recruiting | Early Phase 1 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03684980 | LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma | active not recruiting | Early Phase 1 | 58 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03763162 | Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02106988 | Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma | active not recruiting | Phase 2 | 26 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT02514083 | A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL | active not recruiting | Phase 2 | 29 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Apr 14, 2026 | clinicaltrials |
| NCT03192397 | Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 35 | Roswell Park Cancer InstituteOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT01589302 | PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia | active not recruiting | Phase 2 | 154 | Kami Maddocks, MDOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03500445 | Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma | active not recruiting | Phase 2 | 75 | University of ChicagoOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04450173 | Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma | active not recruiting | Phase 2 | 40 | University of California, DavisOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04667663 | CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.(CPD-DARA) | active not recruiting | Phase 1 | 16 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05208086 | Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma(RHUMM) | active not recruiting | — | 180 | Intergroupe Francophone du MyelomeNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 30, 2026source: clinicaltrials